Eiger BioPharmaceuticals Inc. (EIGR) announced Tuesday morning that its Phase 2 study of ubenimex in pulmonary arterial hypertension demonstrated no improvement for both the primary endpoint of pulmonary vascular resistance and the secondary endpoint of 6-minute walk distance.
from RTT - Before the Bell http://ift.tt/2riuJzn
via IFTTT
No comments:
Post a Comment